• How can the hematologic toxicities with Ven+Aza be managed more effectively?

  • Jul 8 2021
  • Duración: 20 m
  • Podcast

How can the hematologic toxicities with Ven+Aza be managed more effectively?

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • During the 2021 ASCO Annual Meeting, the MDS Hub spoke with Jacqueline S. Garcia, Dana-Farber Cancer Institute, Boston, US, and Amer M. Zeidan, Yale School of Medicine, New Haven, US. We asked, How can the hematologic toxicities with Ven+Aza be managed more effectively.

    Garcia discusses data from a dose-escalation phase Ib study (NCT02942290), evaluating Ven+Aza for the treatment of treatment-naïve patients with high-risk MDS. Garcia reports the promising efficacy and safety results seen in the trial.


    Hosted on Acast. See acast.com/privacy for more information.
    Más Menos
Más Menos
adbl_web_global_use_to_activate_webcro768_stickypopup

Lo que los oyentes dicen sobre How can the hematologic toxicities with Ven+Aza be managed more effectively?

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles